Acurx Pharmaceuticals Sets August 14 for Q2 2026 Earnings Call and Business Update
ACXP is trading near its 52-week low of $1.326 (11% above the low).
Summary
Acurx Pharmaceuticals will host a conference call on August 14, 2026, to discuss Q2 2026 financial results and provide a business update. This follows the Q1 2026 report which showed a net loss and a going concern warning, alongside recent dilutive offerings. The upcoming call is important for investors to assess the company's financial stability and progress on its lead antibiotic candidate, ibezapolstat, given its precarious cash position. Investors will be watching for updates on cash runway and clinical trial developments.
At the time of this announcement, ACXP was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $1.33 to $11.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.